Implication of reported viral hepatitis incidence rate change in Hubei Province, China, between 2004–2010

Abstract

This study examined the change of reported incidence rate for viral hepatitis in Hubei province, China, between 2004 to 2010 to provide scientific evidence for viral hepatitis control. Reported viral hepatitis infection cases were queried from Centre for Disease Control of Hubei Province, China. The incidence of viral hepatitis A decreased steadily across the study period. Viral hepatitis B composed 85% of the viral hepatitis cases. When reported incidence rates for chronic hepatitis B increased, the rates of acute and unclassified cases dropped from 2005 to 2010. The reported viral hepatitis B incidence rate for males was around 1.5–2 times higher than for females. The average annual percentage change of reported viral hepatitis B incidence rates was 4%. The same index for viral hepatitis C was 28%. The reported viral hepatitis B incidence rate of people under 20 years old declined over the period. This decrease was mainly attributed to the recent implementation of vaccination plan. Reported incidence rate of viral hepatitis E also rose in those years. Having a better understanding on reported incidence rates of the present surveillance system is important for developing strategies for further prevention of viral hepatitis. In addition, the data showed that a surveillance system that differentiates new and former infected cases will be more effective in providing evidence for disease control.

Keywords

viral hepatitis / reported incidence rate / vaccination / prevention

References

[1] MahoneyF.J.. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev, 1999, 12(2): 351-366

[2] Viral Hepatitis in the WHO South-East Asia Region. Know it. Confront it. Hepatitis affects everyone, everywhere [Z]. http://www.searo.who.int/linkfiles/diarrhoea, _ari_and_hepatitis_sea-cd-232.pdf: WHO publication, 2011.

[3] XuZ.Y., LiZ.H., WangJ.X., et al.. Ecology and prevention of a shellfish-associated hepatitis A epidemic in Shanghai, China. Vaccine, 1992, 10(Suppl1): S67-S68

[4] WedemeyerH.. Hepatitis D revival. Liver Int, 2011, 31(Suppl1): 140-144

[5] AdamsonR., ReddyV., JonesL., et al.. Epidemiology and burden of hepatitis A, malaria, and typhoid in New York City associated with travel: implications for public health policy. Am J Public Health, 2010, 100(7): 1249-1252

[6] PerzJ.F., ArmstrongG.L., FarringtonL.A., et al.. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol, 2006, 45(4): 529-538

[7] WilliamsI.T., GoldsteinS.T., TufaJ., et al.. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatr Infect Dis J, 2003, 22(2): 157-163

[8] HallidayJ., KlenermanP., BarnesE.. Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines, 2011, 10(5): 659-672

[9] ShepardC.W., FinelliL., AlterM.J.. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis, 2005, 5(9): 558-567

[10] LiangT.J., RehermannB., SeeffL.B., et al.. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med, 2000, 132(4): 296-305

[11] MartinsT., Narciso-SchiavonJ.L., SchiavonL.L.. Epidemiology of hepatitis C virus infection. Rev Assoc Med Bras, 2011, 57(1): 107-112

[12] ShermanM.. Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment. Cleve Clin J Med, 2009, 76(Suppl3): S6-S9

[13] IshikawaT.. Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients. World J Gastroenterol, 2008, 14(40): 6140-6144

[14] ChoiB.C., MorrisonH., WongT., et al.. Bringing chronic disease epidemiology and infectious disease epidemiology back together. J Epidemiol Community Health, 2007, 61(9): 832

[15] LehmanE.M., WilsonM.L.. Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis. Int J Cancer, 2009, 124(3): 690-697

[16] BaigS.. Gender disparity in infections of Hepatitis B virus. J Coll Physicians Surg Pak., 2009, 19(9): 598-600

[17] DattaS., BiswasA., ChandraP.K., et al.. Molecular epidemiology and clinical significance of hepatitis B virus genotypes, core promoter and precore mutations in eastern India. Intervirology, 2008, 51(4): 275-284

[18] RimselieneG., NilsenO., KlovstadH., et al.. Epidemiology of acute and chronic hepatitis B virus infection in Norway, 1992–2009. BMC Infect Dis, 2011, 11: 153

[19] NelsonP.K., MathersB.M., CowieB., et al.. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet, 2011, 378(9791): 571-583

[20] EnaJ., Ruiz-De-ApodacaR.F., PasquauF., et al.. Cross-sectional epidemiology of hepatitis C virus detection and treatment in HIV-infected patients. Eur J Intern Med, 2011, 22(1): 66-72